Short answer
Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease.
Septerna, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease
- Preclinical SEP-204 data reported at the 2026 American Thyroid Association Annual Meeting
- Updated corporate presentation signals additional investor-facing program information
- Investors should review Exhibits 99.1 and 99.2 for supporting data and development details
Item EX-99.1 · Exhibit EX-99.1
- SEP-204 selected as potential first-in-class oral TSHR NAM for Graves’ disease and thyroid eye disease
- Preclinical models showed normalized T4, reduced thyroid enlargement and reduced orbital proptosis
- Projected human half-life of 20-40 hours supports anticipated once-daily dosing
- Generally well tolerated in 28-day GLP toxicology studies in rats and dogs
- Phase 1 healthy-volunteer trial planned for Q1 2027, creating a key clinical execution milestone
Item EX-99.2 · Exhibit EX-99.2
- SEP-479 Phase 1 SAD/MAD data anticipated Q1 2027, with observed 3-4 day half-life supporting once-daily dosing
- SEP-204 Phase 1 initiation anticipated Q1 2027 for Graves’ disease and thyroid eye disease
- SEP-631 Phase 1 showed robust pharmacodynamics, >99% receptor occupancy, and approximately 24-hour half-life supporting once-daily dosing
- SEP-631 produced no severe or serious adverse events, with adverse-event rates comparable to placebo
- Novo collaboration includes $195M upfront, approximately $500M milestones per program, and mid-to-high single-digit tiered royalties
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Septerna, Inc. 8-K filings
Get the next SEPN 8-K as it lands
Follow SEPN for push alerts, or ask the research agent what this filing means.